# Adjuvant Therapy With Anlotinib for HCC

> **NCT04947371** · PHASE2 · WITHDRAWN · sponsor: **Shanghai Zhongshan Hospital**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT04947371
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-15
- **Primary completion:** 2019-03-30
- **Final completion:** 2019-03-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The standard of care of adjuvant therapy for liver cancer was changed.
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04947371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04947371, "Adjuvant Therapy With Anlotinib for HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04947371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*